Methods for the treatment of hepatitis b and hepatitis d infections
AssigneeReplicor, Inc.
InventorsMichel Bazinet, Andrew Vaillant
Life of this patent
Estimating the term…
Abstract
It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
Claims98
Use of a first pharmaceutically acceptable agent which removes hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent that stimulates immune function for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises one or more molecules selected from the group consisting of:
- An antibody targeting the hepatitis B surface antigen;
- The following triazolopyrimidine derivatives:
- An oligonucleotide selected from the following:
- SEQ ID NO:
- 2;
- SEQ ID NO:
- 3;
- SEQ ID NO 10;
- SEQ ID NOs:
- 1 and 4-9;
- A nucleic acid polymer selected from the following:
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;
- An antisense oligonucleotide targeting any part of any HBV mRNA;
- An antisense oligonucleotide targeting any part of the human apolipoprotein H mRNA;
- A siRNA targeting any part of any HBV mRNA;
- A siRNA targeting any part of the human apolipoprotein H mRNA;
- A shRNA targeting any part of any HBV mRNA;
- A shRNA targeting any part of the human apolipoprotein H mRNA;
- A Speigelmer or aptamer targeting the hepatitis B surface antigen;
- and
- A Speigelmer or aptamer targeting human apoliporotein H;
- and a second pharmaceutically acceptable agent which comprises one or more molecules from the group consisting of:
- Thymosin α1;
- Any α-interferon or pegylated derivatives thereof;
- Any β-interferon or pegylated derivatives thereof;
- Any γ-interferon or pegylated derivatives thereof;
- Any λ-interferon or pegylated derivatives thereof;
- interferon α-2a or α-2b or α-N3;
- Interferon β-1a or β-1b;
- Interferon γ-1b;
- Interferon λ1 or λ2 or λ3
- Pegylated interferon α-2a or α-2b or λ1 or λ2;
- Any antiviral cytokine or pegylated derivatives thereof;
- Thymic protein A;
- Any polypeptide shown to have antiviral activity or immunostimulatory activity;
- An immunostimulatory oligonucleotide, including IMO-2055 or IMO-2125;
- A small molecule Toll-like receptor (TLR) agonist;
- and
- Any antiviral or immunostimulatory hormone,
- for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of method for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises thymosin α1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises thymosin α1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises thymosin α1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises thymosin α1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises thymosin α1a for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises thymosin α1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises interferon α-2b for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
Use of a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises GS-9620 for the treatment of hepatitis B infection or of hepatitis B/hepatitis D co-infection.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which removes hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent that stimulates immune function.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises one or more molecules selected from the group consisting of:
- An antibody targeting the hepatitis B surface antigen;
- The following triazolopyrimidine derivatives:
- An oligonucleotide selected from the following:
- SEQ ID NO:
- 2;
- SEQ ID NO:
- 3;
- SEQ ID NO 10;
- SEQ ID NOs:
- 1 and 4-9;
- A nucleic acid polymer selected from the following:
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and
- A phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;
- An antisense oligonucleotide targeting any part of any HBV mRNA;
- An antisense oligonucleotide targeting any part of the human apolipoprotein H mRNA;
- A siRNA targeting any part of any HBV mRNA;
- A siRNA targeting any part of the human apolipoprotein H mRNA;
- A shRNA targeting any part of any HBV mRNA;
- A shRNA targeting any part of the human apolipoprotein H mRNA;
- A Speigelmer or aptamer targeting the hepatitis B surface antigen;
- and
- A Speigelmer or aptamer targeting human apoliporotein H;
- and a second pharmaceutically acceptable agent which comprises one or more molecules from the group consisting of:
- Thymosin α1;
- Any α-interferon or pegylated derivatives thereof;
- Any β-interferon or pegylated derivatives thereof;
- Any γ-interferon or pegylated derivatives thereof;
- Any λ-interferon or pegylated derivatives thereof;
- Interferon α-2a or α-2b or α-N3;
- Interferon β-1a or β-1b;
- Interferon β-1b;
- Interferon λ1 or λ2 or λ3
- Pegylated interferon α-2a or α-2b or λ1 or λ2;
- Any antiviral cytokine or pegylated derivatives thereof;
- Thymic protein A;
- Any polypeptide shown to have antiviral activity or immunostimulatory activity;
- An immunostimulatory oligonucleotide, including IMO-2055 or IMO-2125;
- A small molecule Toll-like receptor (TLR) agonist;
- and
- Any antiviral or immunostimulatory hormone.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon α-2a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises thymosin α1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises thymosin α1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises thymosin α1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises thymosin α1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises thymosin α1a.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises thymosin α1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises interferon α-2b.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises pegylated interferon λ1.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises GS-9620.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 2 and a second pharmaceutically acceptable agent which comprises GS-9620.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises GS-9620.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 3 and a second pharmaceutically acceptable agent which comprises GS-9620.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises GS-9620.
A composition for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, said composition comprising a first pharmaceutically acceptable agent which comprises an oligonucleotide chelate complex of SEQ ID NO:
- 10 and a second pharmaceutically acceptable agent which comprises GS-9620.
Dependencies are inferred from the claim text.